|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Circadian Rhythms
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis of insomnia complaints identifies risk genes and genetic overlap with psychiatric and metabolic traits.
|
28604731 |
2017 |
|
Circadian Rhythms
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank.
|
26955885 |
2016 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Metabolic Syndrome X
|
0.020 |
Biomarker
|
disease |
BEFREE |
Neointimal hyperplasia in MetS and high-glucose-induced VSMC hyperproliferation were measured after infection with adenoviruses encoding RNF10 (Ad-RNF10), short hairpin RNF10 (Ad-shRNF10), or green fluorescent protein (Ad-GFP).
|
30597731 |
2019 |
|
Neointimal hyperplasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
In contrast, Ad-shRNF10 had an opposite effect on neointimal hyperplasia and VSMC hyperproliferation in vivo and in vitro.
|
30597731 |
2019 |
|
Metabolic Syndrome X
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we explored whether RNF10 over-expression prevents neointimal hyperplasia in a MetS rat model and in cultured VSMCs exposed to high glucose.
|
29723537 |
2018 |
|
Neointimal hyperplasia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we explored whether RNF10 over-expression prevents neointimal hyperplasia in a MetS rat model and in cultured VSMCs exposed to high glucose.
|
29723537 |
2018 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
RNF10 may be a next drug target for treating vascular restenosis and other related cardiovascular diseases.© 2018 IUBMB Life, 71(5):632-642, 2019.
|
30597731 |
2019 |
|
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
These outcomes revealed that the differential expression of RNF10 had a completely opposite effect on vascular damage under hyperglycaemia, further displaying the core function of RNF10 in regulating vascular remodeling induced by diabetes.
|
31173254 |
2019 |
|
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
These outcomes revealed that the differential expression of RNF10 had a completely opposite effect on vascular damage under hyperglycaemia, further displaying the core function of RNF10 in regulating vascular remodeling induced by diabetes.
|
31173254 |
2019 |
|
Diabetic Angiopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
Consequently, RNF10 could be a novel target for the treatment of diabetic vascular complications.
|
31173254 |
2019 |
|
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These outcomes revealed that the differential expression of RNF10 had a completely opposite effect on vascular damage under hyperglycaemia, further displaying the core function of RNF10 in regulating vascular remodeling induced by diabetes.
|
31173254 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CYB5A, which has a role in stearyl-CoA-desaturase activity, and RNF10, with an unknown role in weight regulating pathways, associated with adiposity and nominally increased the risk for T2D in American Indians.
|
24151200 |
2014 |